{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:07:59Z","timestamp":1784092079378,"version":"3.55.0"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Management of Chronic lymphocytic leukemia (CLL) has undergone a paradigm shift, moving from chemoimmunotherapy (CIT) to precision, biology-driven treatment with targeted agents. While these advances have rapidly reshaped practice in high-resource nations, their integration into routine care in India is limited by differences in epidemiology, healthcare infrastructure, drug access, and economic constraints. CLL remains relatively uncommon in India, with patients presenting at a younger age and historically at more advanced stages of disease. Nevertheless, there is a temporal shift towards earlier diagnosis with the wider use of hematological testing. Risk stratification has also evolved from clinical staging to molecular profiling incorporating TP53 mutation testing, IGHV mutation status, and cytogenetic abnormalities. However, access to molecular profiling remains limited across India, directly influencing therapeutic decision-making. Bruton tyrosine kinase inhibitors (BTKi) and BCL-2 inhibitors have demonstrated superior efficacy and tolerability compared to CIT across biological subgroups and are endorsed by international guidelines. In India, treatment selection continues to balance biological risk with access and affordability. The introduction of generic ibrutinib has been important, especially for TP53 mutated CLL, while uptake of venetoclax-based fixed-duration regimens has been limited by cost and monitoring requirements. CIT retains a limited role in selected young, IGHV-mutated patients with durable responses. This review examines contemporary CLL management through an Indian lens, emphasizing how global advances intersect with real-world constraints and influence local practice. Improving access to molecular diagnostics and targeted agents along with health-policy reforms is essential to narrow the outcome gap between Indian and Western patients with CLL.<\/jats:p>","DOI":"10.3389\/fonc.2026.1853089","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:42:59Z","timestamp":1784090579000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic lymphocytic leukemia management in India: balancing evidence, access, and affordability in clinical practice"],"prefix":"10.3389","volume":"16","author":[{"given":"Shubham","family":"Sahni","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences (AIIMS)","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lata","family":"Rani","sequence":"additional","affiliation":[{"name":"Genomics Lab, Centralized Core Research Facility (CCRF), All India Institute of Medical Sciences","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Gupta","sequence":"additional","affiliation":[{"name":"Laboratory Oncology Unit, Dr. B. R. A. Institute Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences (AIIMS)","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Gogia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences (AIIMS)","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/go.20.00032","article-title":"Chronic lymphocytic leukemia: Real-world data from India","volume":"6","author":"Tejaswi","year":"2020","journal-title":"JCO Global Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v13i5.6529","article-title":"Beyond guidelines: Real world treatment & outcomes of chronic lymphocytic leukemia at a tertiary Indian cancer centre","volume":"13","author":"Jacob","year":"2025","journal-title":"MRAJ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11899-023-00722-7","article-title":"How do we manage chronic lymphocytic leukemia in India","volume":"19","author":"Karunakaran","year":"2024","journal-title":"Curr Hematol Malig Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1359-6349(10)70680-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2023.100201","article-title":"Cost-effectiveness analysis of different combination therapies for the treatment of chronic lymphocytic leukaemia in India","volume":"13","author":"Nehra","year":"2023","journal-title":"Lancet Regional Health - Southeast Asia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214346","article-title":"Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Cl\u00ednic of Barcelona experience","volume":"114","author":"Abrisqueta","year":"2009","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/10245330701255064","article-title":"Chronic lymphocytic leukemia in India-A clinico-hematological profile","volume":"12","author":"Agrawal","year":"2007","journal-title":"Hematology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.672734","article-title":"Assessment of 285 cases of chronic lymphocytic leukemia seen at single large tertiary center in Northern India","volume":"53","author":"Gogia","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B9","doi-asserted-by":"publisher","first-page":"638","DOI":"10.4103\/crst.crst_215_20","article-title":"Outcome of chronic lymphocytic leukemia with deletion 17p","volume":"3","author":"Gogia","year":"2020","journal-title":"Cancer Res Stat Treat"},{"key":"B10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4103\/sajc.sajc_287_18","article-title":"Chronic lymphocytic leukemia with deletion 17p: An Indian scenario","volume":"8","author":"Gogia","year":"2019","journal-title":"South Asian J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.02.007","article-title":"Prognostic and predictive significance of smudge cell percentage on routine blood smear in chronic lymphocytic leukemia","volume":"14","author":"Gogia","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41408-019-0272-y","article-title":"RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome","volume":"10","author":"Kaur","year":"2020","journal-title":"Blood Cancer J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2004.05.001","article-title":"Chronic lymphocytic leukemia","volume":"11","author":"Chiorazzi","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1182\/blood.v120.21.3888.3888","article-title":"Role of PET\/CT in the diagnostic work-up of patients with chronic lymphocytic leukemia (CLL) and clinical signs of disease progression","volume":"120","author":"Mauro","year":"2012","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1182\/blood.v128.22.5574.5574","article-title":"CLL in India may have a different biology from that in the West","volume":"128","author":"Saxena","year":"2016","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia","volume":"100","author":"Kr\u00f6ber","year":"2002","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718494","article-title":"Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling","volume":"129","author":"Myklebust","year":"2017","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3525-0","article-title":"Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort","volume":"98","author":"Rani","year":"2019","journal-title":"Ann Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010845","article-title":"The CLL12 trial: ibrutinib vs placebo in treatment-na\u00efve, early-stage chronic lymphocytic leukemia","volume":"139","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.10.861","article-title":"Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials","volume":"91","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.187583","article-title":"TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics","volume":"103","author":"Campo","year":"2018","journal-title":"Haematologica"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1817073","article-title":"Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of adverse effects\/toxicity of ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"B37","article-title":"Six-year update of the ELEVATE-TN study on acalabrutinib","volume":"22","author":"Sharman","year":"2024","journal-title":"Clin Adv Hematol Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-018-1011-4","article-title":"Reduced dose ibrutinib due to financial toxicity in CLL","volume":"35","author":"Lad","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4103\/ijmpo.ijmpo_43_17","article-title":"Efficacy and safety of ibrutinib in Indian patients with relapsed or refractory chronic lymphocytic leukemia and mantle cell lymphoma: cases from a named patient program","volume":"38","author":"Agarwal","year":"2017","journal-title":"Indian J Med Paediatric Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01580","article-title":"Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","author":"Kater","year":"2019","journal-title":"JCO"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evidence"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020158","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10720","article-title":"Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival","volume":"92","author":"Stilgenbauer","year":"2007","journal-title":"Haematologica"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-020-01378-6","article-title":"Efficacy, safety, and quality of life of generic and innovator ibrutinib in Indian CLL patients","volume":"37","author":"Singh","year":"2021","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-764712","article-title":"How I treat CLL patients with ibrutinib","volume":"131","author":"Brown","year":"2018","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.96","article-title":"Practical management of tumour lysis syndrome in venetoclax\u2010treated patients with chronic lymphocytic leukaemia","volume":"188","author":"Gribben","year":"2020","journal-title":"Br J Haematol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/go.20.00012","article-title":"Comparison of access to novel drugs for lymphoma and chronic lymphocytic leukemia between India and the United States","volume":"6","author":"Sathyanarayanan","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.99794","article-title":"Patterns of Bruton\u2019s tyrosine kinase inhibitor (BTKi) usage in B-cell lymphomas in India: a questionnaire-based study","volume":"17","author":"Naseem","year":"2025","journal-title":"Cureus"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"key":"B57","unstructured":"FDA grants traditional approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma\n          \n          \n          \n          2025"},{"key":"B58","unstructured":"U.S. FDA approves bristol myers squibb\u2019s breyanzi \u00ae as the first and only CAR T cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)\n          \n          \n          \n          2024"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071290","article-title":"Innovative combinations, cellular therapies and bispecific antibodies for chronic lymphocytic leukemia: a narrative review","volume":"16","author":"Visentin","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1719099","article-title":"Modified CLL International Prognostic Index (CLL-LIPI) using lymphocyte doubling time (LDT) in place of IgHV mutation status in resource-limited settings predicts time to first treatment and overall survival","volume":"61","author":"Lad","year":"2020","journal-title":"Leukemia Lymphoma"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1853089\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:43:08Z","timestamp":1784090588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1853089\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":60,"alternative-id":["10.3389\/fonc.2026.1853089"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1853089","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1853089"}}